Evidence map›Paper›PMID 39183927›Full record

ArticleChemical science2024

Dual inhibitors of

Olga Metelkina, Jelena Konstantinović, Andreas Klein, Roya Shafiei, Mario Fares, Alaa Alhayek, Samir Yahiaoui, Walid A M Elgaher, Jörg Haupenthal, Alexander Titz and 1 more

Abstract read
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. α-Mangostin attenuatesVirulence · 2026
    Article
  2. Exploring the Role ofACS infectious diseases · 2026
    Article
  3. Review
  4. Article
  5. Mechanisms ofMedicina (Kaunas, Lithuania) · 2026
    Review
  6. Anti-QS Strategies AgainstMicroorganisms · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Olga MetelkinaHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.ORCID https://orcid.org/0000-0001-9543-2583
Jelena KonstantinovićHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.ORCID https://orcid.org/0000-0002-2572-8538
Andreas KleinHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.
Roya ShafieiHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.
Mario FaresHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.
Alaa AlhayekHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.
Samir YahiaouiHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.
Walid A M ElgaherHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.ORCID https://orcid.org/0000-0002-8766-4568
Jörg HaupenthalHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.ORCID https://orcid.org/0000-0003-3991-2800
Alexander TitzHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.ORCID https://orcid.org/0000-0001-7408-5084
Anna K H HirschHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) Campus E8.1 66123 Saarbrücken Germany alexander.titz@helmholtz-hips.de anna.hirsch@helmholtz-hips.de.ORCID https://orcid.org/0000-0001-8734-4663

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dual inhibitors of two key virulence factors of

Identifiers

PMID39183927
PMCPMC11339798

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.